2014 M560191). Author details 1 Department of Nephrology, Tianjin
Dation funded project (No. 2014 M560191). Author details 1 Department of Nephrology, Tianjin Medical University General Hospital, Tianjin 300052, China. 2Department of Nephrology, Shandong Provincial Hospital affiliated to Shandong University, Jinan, Shandong 250021, China. 3 Department of Clinical Laboratory, Tianjin Medical University General Hospital, Tianjin 300052, China. 4Key Lab of Hormones and Development (Ministry of Health), Metabolic PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/9547713 Diseases Hospital Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China. Received: 26 October 2014 Accepted: 19 FebruaryReferences 1. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352:351?1. 2. von Scheven E, Lu TT, Emery HM, Elder ME, Wara DW. Thrombosis and pediatric Wegener’s granulomatosis: acquired and genetic risk factors for hypercoagulability. Arthritis Rheum. 2003;49:862?. 3. Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis Jr JC, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142:620?. 4. Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2006;55:146?. 5. Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis ncidence and risk factors. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/20460822 Rheumatology (Oxford). 2008;47:530?. 6. Tomasson G, Lavalley M, Tanriverdi K, 4-Dichloropyrimidine-5-carboxylate 7-Methoxy-1H-indole 1-((3-Nitrophenyl)sulfonyl)piperidine-3-carboxylic acid (R Finkielman JD, Davis Jr JC, Hoffman GS, et al. Relationship between (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4,4-dimethylpentanoic acid markers of platelet activation and inflammation with disease activity in Wegener’s granulomatosis. J Rheumatol. 2011;38:1048?4. 7. Ma TT, Huang YM, Wang C, Zhao MH, Chen M. Coagulation and fibrinolysis index profile in patients with ANCA-associated vasculitis. PLoS One. 2014;9:e97843. 8. Kalsch AI, Csernok E, Munch D, Birck R, Yard BA, Gross W, et al. Use of highly sensitive C-reactive protein for followup of Wegener’s granulomatosis. J Rheumatol. 2010;37:2319?5. 9. Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, Lu W, et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). Faseb J. 2007;21:284?4. 10. Molins B, Pena E, Vilahur G, (S)-tert-Butyl 6-(hydroxymethyl)-5-azaspiro[2.4]heptane-5-carboxylate Mendieta C, Slevin M, Badimon L. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol. 2008;28:2239?6.11. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res. 2009;105:128?7. 12. Boncler M, Rywaniak J, Sicinska P, Watala C. Effectiveness of modified C-reactive protein in the modulation of platelet function under different experimental conditions. Blood Coagul Fibrinolysis. 2011;22:301?. 13. Nakazawa D, Shida H, Tomaru U, Yoshida M, Nishio S, Atsumi T, et al. Enhanced formation and disordered regulation of NETs in myeloperoxidaseANCA-associated microscopic polyangiitis. J Am Soc Nephrol. 2014;25:990?. 14. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15:623?. 15. Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, et al. Neutrophil extracel.